A Randomized, Double-Blind, Placebo-Controlled Phase I Trial to Evaluate the Immunomodulatory Effect of RUTI® in Individuals With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Treated With Intravesical Bacillus Calmette-Guerin (BCG)
Phase of Trial: Phase II
Latest Information Update: 22 Jan 2018
At a glance
- Drugs Tuberculosis vaccine (Primary)
- Indications Tuberculosis
- Focus Pharmacodynamics
- Acronyms RUTIVAC-1
- Sponsors Archivel Farma
- 12 Jan 2018 Status changed from recruiting to suspended due to Study Product not avaliable.
- 20 Jun 2017 Status changed from not yet recruiting to recruiting.
- 23 Feb 2017 New trial record